Table S6 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Sarah P. Suehnholz,Moriah H. Nissan, Hongxin Zhang,Ritika Kundra, Subhiksha Nandakumar,Calvin Lu,Stephanie Carrero,Amanda Dhaneshwar,Nicole Fernandez,Benjamin Xu,Maria E. Arcila, Ahmet Zehir,Aijazuddin Syed,A. Rose Brannon,Julia E. Rudolph,Eder Paraiso, Paul Sabbatini,Ross L. Levine, Ahmet Doğan, Jianjiong Gao,Marc Ladanyi,Alexander Drilon, Michael F. Berger,David B. Solit,Nikolaus Schultz,Debyani Chakravarty

openalex

引用 0|浏览6

暂无评分

摘要

Table S6: Gene-alteration-tumor types associated with an OncoKB Therapeutic Level of Evidence (Levels 1-4) in March 2017, and changes made to the dataset to ensure 2017 OncoKB clinically actionable variants are consistent with the OncoKB Standard Operating Procedure v2.2.

查看译文

关键词

Cancer Genomics,Cancer Therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要